Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ49IJ
|
|||
| Drug Name |
Imsidolimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Generalized pustular psoriasis [ICD-11: EA90.40] | Phase 3 | [1] | |
| Company |
AnaptysBio San Diego, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | IL-1 receptor-like 2 (IL1RL2) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05366855) A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis. U.S.National Institutes of Health. | |||
| REF 2 | Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023 Jul 17;189(2):161-169. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.